Since its creation in 2017, Hepatitis C: State of Medicaid Access has evaluated hepatitis C treatment policies across state Medicaid programs based on three criteria: liver disease severity (“fibrosis”), alcohol and drug use (“sobriety”), and prescriber limitations. In response to advocacy and litigation, these restrictions have been reduced or eliminated in many states, increasing access to lifesaving treatment. Yet significant barriers remain. Join us for a webinar to hear more about the next phase of Hepatitis C: State of Medicaid Access, which considers new and existing barriers to treatment access and dives deeper into the role that state Medicaid programs play in progressing towards a country free of viral hepatitis.